All Clinical Trials
Official Title Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B
Phase Phase III
ClinicalTrials.gov NCT01940341
Treatments
Tenofovir alafenamide
, Tenofovir alafenamide
Tradename:VemlidyOther Names:TAF, Tenofovir AFClass:Oral Antivirals (Nucleos(t)ide Analogues)Tenofovir DF
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Oral Antivirals (Nucleos(t)ide Analogues)Funding
IndustryGilead Sciences
References
- Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196-206.
- Cathcart AL, Chan HL, Bhardwaj N, et al. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrob Agents Chemother. 2018;62(10).pii: e01064-18
Official Title Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B
Phase Phase III
ClinicalTrials.gov NCT01940471
Treatments
Tenofovir alafenamide
, Tenofovir alafenamide
Tradename:VemlidyOther Names:TAF, Tenofovir AFClass:Oral Antivirals (Nucleos(t)ide Analogues)Tenofovir DF
Tenofovir DF
Tradename:VireadOther Names:TDF, tenofovir disoproxil fumarateClass:Oral Antivirals (Nucleos(t)ide Analogues)Funding
IndustryGilead Sciences
References
- Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185-95.